{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T23:20:40Z","timestamp":1771629640651,"version":"3.50.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1097\/jcp.0b013e3182742ea4","type":"journal-article","created":{"date-parts":[[2012,11,6]],"date-time":"2012-11-06T10:17:20Z","timestamp":1352197040000},"page":"750-755","source":"Crossref","is-referenced-by-count":6,"title":["Excessive Insulin Secretion in Japanese Schizophrenic Patients Treated With Antipsychotics Despite Normal Fasting Glucose Levels"],"prefix":"10.1097","volume":"32","author":[{"given":"Takuro","family":"Sugai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzo","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuto","family":"Tsuneyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Someya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1749-6632.1987.tb36212.x","article-title":"Induction of obesity by psychotropic drugs.","volume":"499","author":"Bernstein","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":". Antipsychotic-induced weight gain: a comprehensive research synthesis.","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R3-3-20210128","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4088\/JCP.v66n0318a","article-title":"Antipsychotic medication and diabetes mellitus.","volume":"66","author":"Citrome","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-0447.2008.01158.x","article-title":". Diabetes and schizophreniaeffect of disease or drug Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia.","volume":"117","author":"Saddichha","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0924-977X(03)00072-5","article-title":"Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro.","volume":"14","author":"Melkersson","year":"2004","journal-title":"Eur Neuropsychopharmacol"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S1461145705005110","article-title":". Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenia subjects.","volume":"8","author":"Smith","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00213-005-0205-2","article-title":"A crossover study on lipid and weight changes associated with olanzapine and risperidone.","volume":"183","author":"Kuan-Pin","year":"2005","journal-title":"Psychopharmacology"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","article-title":". Physical health monitoring of subjects with schizophrenia.","volume":"161","author":"Marder","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"suppl 1","key":"R9-3-20210128","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.","volume":"68","author":"Newcomer","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes.","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.4088\/JCP.v65n1102","article-title":". Metabolic effects of treatment with atypical antipsychotics.","volume":"65","author":"Kane","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-2002-36391","article-title":". Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.","volume":"35","author":"Baptista","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/01.jcp.0000237947.80764.d9","article-title":". The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic subjects.","volume":"26","author":"Chiu","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/JCP.0b013e318184b4c5","article-title":". Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration.","volume":"28","author":"Chintoh","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.npp.1301142","article-title":". Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis.","volume":"32","author":"Vestri","year":"2007","journal-title":"Neuropsychopharmacol"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/jn\/136.5.1352","article-title":". Dietary patterns and glucose tolerance abnormalities in Japanese men.","volume":"136","author":"Mizoue","year":"2006","journal-title":"J Nutr"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"a236","DOI":"10.1136\/bmj.39582.447998.BE","article-title":". Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study.","volume":"337","author":"Dale","year":"2008","journal-title":"BMJ"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2337\/dc06-1414","article-title":". The National Cholesterol Education ProgramAdult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes.","volume":"30","author":"Lorenzo","year":"2007","journal-title":"Diabetes Care"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1046\/j.1464-5491.2002.00835.x","article-title":". Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention.","volume":"19","author":"Unwin","year":"2002","journal-title":"Diabet Med"},{"key":"R20-3-20210128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4088\/JCP.07m03829","article-title":". Glucose metabolism in Japanese schizophrenic subjects treated with risperidone or olanzapine.","volume":"70","author":"Yasui-Furukori","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R21-3-20210128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.4088\/JCP.v67n0513","article-title":". Glucose metabolism in subjects with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.","volume":"67","author":"Henderson","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/90984","article-title":". The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Nat Med"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1046\/j.1464-5491.2002.00746.x","article-title":". Diminution of early insulin response to glucose in subjects with normal but minimally elevated fasting plasma glucose. Evidence for early beta-cell dysfunction.","volume":"19","author":"Sato","year":"2002","journal-title":"Diabet Med"},{"key":"R24-3-20210128","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/diab.41.11.1473","article-title":"Molecular mechanisms of insulin resistance.","volume":"41","author":"Taylor","year":"1992","journal-title":"Diabetes"},{"key":"R25-3-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2337\/diab.32.1.35","article-title":"Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man.","volume":"32","author":"De Fronzo","year":"1983","journal-title":"Diabetes"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1161\/01.CIR.93.10.1809","article-title":"Insulin sensitivity and atherosclerosis.","volume":"93","author":"Howard","year":"1996","journal-title":"Circulation"},{"key":"R27-3-20210128","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1172\/JCI33296","article-title":". Cholesterol in islet dysfunction and type 2 diabetes.","volume":"118","author":"Brunham","year":"2008","journal-title":"J Clin Invest"},{"key":"R28-3-20210128","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1210\/en.2009-0252","article-title":". Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells.","volume":"150","author":"Rutti","year":"2009","journal-title":"Endocrinology"},{"key":"R29-3-20210128","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1194\/jlr.P600012-JLR200","article-title":". Common ABCA1 variants, HDL levels, and cellular cholesterol efflux in subjects with familial low HDL.","volume":"48","author":"Soro-Paavonen","year":"2007","journal-title":"J Lipid Res"},{"key":"R30-3-20210128","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2337\/dc09-1562","article-title":". Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction.","volume":"33","author":"Vergeer","year":"2010","journal-title":"Diabetes Care"},{"key":"R31-3-20210128","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5551\/jat.E599","article-title":". Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations.","volume":"16","author":"Koseki","year":"2009","journal-title":"J Atheroscler Thromb"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e3182742ea4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T03:28:35Z","timestamp":1714534115000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201212000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3182742ea4","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}